IDEAS home Printed from https://ideas.repec.org/h/spr/mgmchp/978-3-031-50032-9_23.html
   My bibliography  Save this book chapter

Case 23 Vertex Pharmaceuticals

In: Rising Stars

Author

Listed:
  • B. Rajesh Kumar

    (Institute of Management Technology)

Abstract

Vertex Pharmaceuticals is a global biotechnology company which focuses on specialty markets to create innovative medicines for treating serious diseases like cystic fibrosis. Vertex have a pipeline of investigational therapies to find cure for diseases like sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The four medicines TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO are used to treat over 83,000 people for cystic fibrosis in regions of North America, Europe, and Australia. As of December 31, 2021, the company had approximately 3900 employees. The common stock of Vertex is traded on Nasdaq Global Select Market under the symbol “VRTX.” The company has headquarters in Boston and London. Vertex focuses on investment in R&D to discover and develop innovative medicines by combining transformative advances in the field of human diseases and the science of therapeutics. Vertex focuses on strategic alliances and M&A as a part of its growth strategy. An investment of $100 in the Vertex Pharma stock on July 24,1991 would have led to the invested amount accumulated to $7141.56 by December 3, 2022, reflecting a return of 7041.56%. The total cumulative monthly return for Vertex stock was 82.6% during the period 2018–2022.

Suggested Citation

  • B. Rajesh Kumar, 2024. "Case 23 Vertex Pharmaceuticals," Management for Professionals, in: Rising Stars, pages 177-183, Springer.
    • Handle: RePEc:spr:mgmchp:978-3-031-50032-9_23
    DOI: 10.1007/978-3-031-50032-9_23
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:mgmchp:978-3-031-50032-9_23. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.